This shared observation underscores the need to validate TME CD14+ infiltration as a prognostic marker in lung cancer, and for further studies to identify the immune and non-immune mechanisms by which CD14+ cells influence patient outcomes. This evidence concerns the gene CD14 and lung cancer.